ANDROGEN RECEPTOR HETEROGENEITY IN HUMAN PROSTATIC CARCINOMAS VISUALIZED BY IMMUNOHISTOCHEMISTRY
ANDROGEN RECEPTOR HETEROGENEITY IN HUMAN PROSTATIC CARCINOMAS VISUALIZED BY IMMUNOHISTOCHEMISTRY
复制标题
DOI：
10.1002/path.1711600409
复制
发表时间：
1990-04-01
影响因子：
7.3
通讯作者：
VANDERKWAST, TH
中科院分区：
文献类型：
--
作者：
DEWINTER, JAR;TRAPMAN, J;VANDERKWAST, TH
通过使用与人雄激素受体 N 末端结构域具有反应性的多克隆抗体进行免疫组织化学染色，检查了 26 例原发性前列腺癌中人雄激素受体的表达。十八个癌症显示出雄激素受体的均匀染色，而在七个病例中发现受体表达存在相当大的异质性。在一种情况下，仅检测到数量非常有限的免疫反应性肿瘤细胞。根据 MD 安德森分级系统，将雄激素受体表达与肿瘤分级评分进行比较，结果表明，在更具侵袭性（III 级）的肿瘤中，免疫染色肿瘤细胞的比例以及免疫染色的强度（在较小程度上）有所降低。利用免疫组织化学检测前列腺癌中雄激素受体的表达可能成为预测激素治疗下前列腺肿瘤行为和预后的新的、灵敏的方法。
Expression of the human androgen receptor was examined in 26 primary prostatic carcinomas by immunohistochemical staining with a polyclonal antibody reactive with the N‐terminal domain of the human androgen receptor. Eighteen carcinomas showed homogeneous staining for the androgen receptor, whereas in seven cases a considerable heterogeneity in expression of the receptor was found. In one case, only a very limited number of immunoreactive tumour cells were detected. Comparison of androgen receptor expression with the tumour grading score, according to the MD Anderson grading system, revealed that the proportion of immunostained tumour cells and—to a lesser extent—the intensity of immunostaining were decreased in the more aggressive (grade III) tumours. The use of immunohistochemistry for detection of expression of androgen rereptor in prostatic carcinomas may become a new and sensitive method for predicting prostatic tumour behaviour under hormonal therapy and prognosis.